ivosidenib

Details

Generic Name:
ivosidenib
Project Status:
Pending
Therapeutic Area:
Acute myeloid leukemia (AML)
Manufacturer:
Servier Canada Inc
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0349-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.